AUTH/3919/6/24 - Complainant v AstraZeneca

Allegations about a product website for members of the public

  • Case number
    AUTH/3919/6/24
  • Complaint received
    05 June 2024
  • Completed
    30 June 2025
  • Appeal hearing
    No appeal
  • Applicable Code year
    2021
  • No breach Clause(s)
  • Breach Clause(s)
  • Sanctions applied
    Undertaking received
  • Additional sanctions

Case Summary

This case was in relation to a list of medicines on AstraZeneca's corporate website. The complainant alleged that the list contained errors related to the presence or absence of the black triangle symbol, and that one medicine was missing from the list.

The outcome under the 2021 Code was: 

Breach of Clause 26.2

Providing inaccurate information for the public

 

No Breach of Clause 2

Requirement that activities or materials must not bring discredit upon, or reduce confidence in, the pharmaceutical industry

No Breach of Clause 5.1

Requirement to maintain high standards at all times

No Breach of Clause 9.1

Requirement that all relevant personnel concerned with the preparation or approval of material or activities covered by the Code must be fully conversant with the Code and the relevant laws and regulations

No Breach of Clause 26.2

Requirement that information about prescription only medicines which is made available to the public must be factual, balanced, must not raise unfounded hopes of successful treatment or encourage the public to ask their health professional to prescribe a specific prescription only medicine

No Breach of Clause 26.4

Requirement to include the black triangle in material which relates to a medicine subject to additional monitoring and that is intended for patients taking that medicine

This summary is not intended to be read in isolation.
For full details, please see the full case report below.